De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis
July 11th 2024Multiple sclerosis (MS) treatment specialists discuss the challenges associated with the early use of high-efficacy therapy (HET) in patients with mild to moderate MS and delve into the broader debate surrounding the consistent use of HET for managing mild to moderate MS cases.
Determining Treatment Success in Spinal Muscular Atrophy
Panelists share their approaches to counseling adult patients with spinal muscular atrophy (SMA) about treatment expectations.
Switching Treatments in Spinal Muscular Atrophy
Key opinion leaders share their strategies for discussing potential changes in therapy and transitioning between treatments with patients, emphasizing the importance of reassuring patients that such changes are intended to provide long-term benefits for managing their spinal muscular atrophy.
The Importance of Open Communication in Patient Care: Kelly Papesh, DNP, APRN, FNP-BC
July 7th 2024The executive director of the Association of Movement Disorder Advanced Practice Providers discussed how effective patient care in movement disorders can lead to better management and treatment outcomes. [WATCH TIME: 4 minutes]
The Challenges and Innovations in Parkinson Treatment: Michael Soileau, MD, FAAN
July 6th 2024The movement disorder specialist at Texas Movement Disorder Specialists talked about the complexities and advancements in treating Parkinson disease, emphasizing the need for strategic and aggressive treatment approaches despite administrative burdens. [WATCH TIME: 5 minutes]
Monitoring Patients With Mild/Moderate Multiple Sclerosis
July 3rd 2024The key opinion leaders provide recommendations on the optimal frequency for evaluating disease progression in patients with mild to moderate MS, emphasizing effective monitoring methods and the most appropriate tools for best clinical practice.
Factors Guiding Treatment Selection in Adult Spinal Muscular Atrophy
Panelists explore critical considerations when choosing a treatment approach for treatment-naïve adult patients with spinal muscular atrophy (SMA), taking into account factors such as disease severity, patient preferences, and potential treatment outcomes.
Treatments Approved for Treatment of Spinal Muscular Atrophy
Key opinion leaders (KOLs) examine the mechanisms of action and other pertinent information regarding FDA-approved treatments for spinal muscular atrophy (SMA), sharing their perspectives on these therapies with a particular focus on the various modes of administration.
Assessing Long-Term Benefit of Eptinezumab for Chronic Migraine: Amaal Starling, MD, FAHS, FAAN
Published: July 1st 2024 | Updated: July 1st 2024The associate professor of neurology at Mayo Clinic College of Medicine discussed findings from a post-hoc analysis of the phase 3 PREVAIL study presented at AHS 2024 assessing eptinezumab in patients with chronic migraine. [WATCH TIME: 4 minutes]
Building a Vibrant Community of Neurology Educators: Tracey Milligan, MD, MS, FAAN, FANA, FAES
Published: June 30th 2024 | Updated: July 1st 2024The professor and chair of neurology at New York Medical College discussed her extensive involvement in neurology education and the recent efforts to enhance neurology education through various programs. [WATCH TIME: 5 minutes]